Melagatran and ximelagatran. Pharmacological characteristics and anaesthesiological aspects;Melagatran und Ximelagatran: Pharmakologische Eigenschaften und anästhesiologische Aspekte

Anaesthesist

Volumn 52, Issue 12, 2003, Pages 1171-1175

  Pindur, G ^a   Ziegeler, S ^a   Kleinschmidt, S ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Anticoagulation; Direct inhibition; Megalatran; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DIPEPTIDE; HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ANESTHESIOLOGY; ANTICOAGULATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG USE; DRUG UTILIZATION; HUMAN; PERIOPERATIVE PERIOD; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ANESTHESIA; ANIMALS; AZETIDINES; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; GLYCINE; HALF-LIFE; HUMANS;

EID: 0347694418     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-003-0602-z     Document Type: Review

References (23)

1. Aken H van, Bode C, Darius H et al. (2001) Anticoagulation: the present and future. Clin Appl Thromb Hemost 7:195-204
2. Bergqvist D, Holmdahl L, Solhaug JH (2001) Efficacy and safety of sc melagatran and oral ximelagatran as prophylaxis against thromboembolic complications following general abdominal surgery. Thromb Haemost 86:0C1020
3. Elg M, Carlsson S, Gustaffson D (2001) Effect of activated prothrombin complex concentrate or recombinant factor Vila on the bleeding time and thrombus formation during anticoagulation with direct thrombin inhibitor. Thromb Res 101:145-157
4. Eriksson BI, Bergqvist D, Kälebo P et al. (2002) Ximelagatran and megalatran compared with dalteparin for the prevention of venous thromboembolism after total hip or knee replacement. The METHRO II randomised trial. Lancet 360:1441-1447
5. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S (2003) A randomized controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 1:41-47
6. Francis CW, Davidson BL, Berkowitz SD et al. (2002) Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 137:648-655
7. Gogarten W, Aken H van, Büttner J, Riess H, Wulf H, Buerkle H (2003) Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/ antithrombotische Medikation. Überarbeitete Leitlinien der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin. Anaesthesiol Intensivmed 44:218-230
8. Gustafsson D, Elg M (2003) The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109 [Suppl 1]:S9-15
9. Gustafsson D, Antonsson T, Bylund R (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110-118
10. Gustafsson D, Nystrom J, Carlsson S (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption, biochemical and pharmacodynamic effects. Thromb Res 101:171-181
11. Haas S (2003) Neue Antikoagulanzien - Bedeutung für die Praxis. Ther Umsch 60:19-23
12. Halperin JL, Executive Steering Committee, SPORTIF III and V Study investigators (2003) Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular fibrillation: rational, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146:431-438
13. Harenberg J, Ingrid J, Tivadar F (2002) Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Isr Med Assoc J 4:1003-1005
14. Heit JA, Colwell CW, Francis CW (2001) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 161:2215-2221
15. Hopfner R (2002) Ximelagatran (AstraZeneca). Curr Opin Investig Drugs 3:246-251
16. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG (2003) Influence of the age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42:381-392
17. Kaplan KL (2003) Direct thrombin inhibitors. Expert Opin Pharmacother 4:653-666
18. Mattson C, Menschiek-Lundin A, Wahlander KI, Lindthal T (2001) Effect of megalatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 86:611-615
19. Moerloose P de, Boehlen F (2002) Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anaesthesia [Deux nouveaux agents antithrombotiques (fondaparinux et ximelagatran) et implications en anesthésie]. Can J Anesth 49 [Suppl 6]:S5-10
20. Nilsson T, Sjöling-Eriksson A, Deinum J (1998) The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J Enzyme Inhib 13:11-29
21. Nowak G (2002) Rationale für einen oralen direkten Thrombininhibitor aus pharmakologischer Sicht. Hämostaseologie 22:92-97
22. Petersen P (2001) A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. SPORTIF II and IV investigators. Blood 98:706a-707a
23. Wallentin L, Wilcox R, Weaver D, Emanuelsson H, Goodvin A, Bylock A, for the ESTEEM investigators (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trail. Lancet 362:789-797